Iridex Corporation (IRIX)
NASDAQ (CM) NASDAQ (CM) Primary 
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
IRIX's Q2 loss per share widens year over year and revenues decline as Middle East disruptions and reduced sell-through in China weigh on retina sales, offsetting continued growth in the Cyclo G6 product family.
IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript
IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth
IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.
IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript
IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript
Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth
IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.
IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript
IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript
Zacks Initiates Coverage of Iridex With Neutral Recommendation
Discover why Zacks initiated coverage of IRIX with a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Learn how global sales momentum and stronger liquidity are balanced against margin pressures and dependency on a key distributor.
IRIDEX Corporation (IRIX) Q3 2025 Earnings Call Prepared Remarks Transcript
IRIDEX Corporation ( IRIX ) Q3 2025 Earnings Call November 11, 2025 5:00 PM EST Company Participants Patrick Mercer - CEO, President & Director Romeo Dizon - Chief Financial Officer Conference Call Participants Philip Taylor - Gilmartin Group LLC Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Third Quarter 2025 IRIDEX Earnings Conference Call.
IRIDEX Corporation (IRIX) Q2 2025 Earnings Call Transcript
IRIDEX Corporation (NASDAQ:IRIX ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Patrick Mercer - CEO, President & Director Romeo R. Dizon - Chief Financial Officer Conference Call Participants Philip Taylor - Gilmartin Group LLC Operator Thank you for standing by.
IRIDEX Corporation, Inc. (IRIX) Q1 2025 Earnings Call Transcript
IRIDEX Corporation, Inc. (NASDAQ:IRIX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Trip Taylor - IR Patrick Mercer - CEO, President & Director Romeo Dizon - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
IRIDEX Changes Course
IRIDEX's strategic review ended without a major asset sale, but a $10M investment from Novel Inspiration International offers growth potential and cash stability. Novel's investment values IRIDEX shares at $2.00/share, significantly higher than current trading prices, indicating a belief in the company's undervaluation. The recent LCD change in glaucoma treatment reimbursement could significantly boost IRIDEX's glaucoma business, potentially increasing the company's market valuation.
IRIDEX Corporation (IRIX) Strategic Vision Conference Call (Transcript)
IRIDEX Corporation (NASDAQ:IRIX ) Strategic Vision Conference Call April 16, 2025 5:00 PM ET Company Participants Trip Taylor - Investor Relations Patrick Mercer - Chief Executive Officer Will Moore - Board of Directors Conference Call Participants Aaron Warwick - Breakout Investors Jason Stankowski - Clayton Partners Mark Gomes - Pipeline Data Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
